This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linares, M. J.
Right arrow Articles by Casal, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linares, M. J.
Right arrow Articles by Casal, M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2005, p. 2520-2522, Vol. 43, No. 5
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.5.2520-2522.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Voriconazole against Prototheca wickerhamii: Comparative Evaluation of Sensititre and NCCLS M27-A2 Methods of Detection

Maria José Linares,* Francisco Solís, and Manuel Casal

Department of Microbiology, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain

Received 31 October 2004/ Returned for modification 8 December 2004/ Accepted 19 January 2005

A total of 104 Prototheca wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of ≤0.5 µg/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% ± 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience.

* Corresponding author. Mailing address: Departamento de Microbiología, Facultad de Medicina, Avda. Menendez Pidal S/N, 14004 Cordoba, Spain. Phone: 345-957-218286. Fax: 34-957-218229. E-mail: mi1lisim{at}uco.es.

Journal of Clinical Microbiology, May 2005, p. 2520-2522, Vol. 43, No. 5
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.5.2520-2522.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tortorano, A. M., Prigitano, A., Dho, G., Piccinini, R., Dapra, V., Viviani, M. A. (2008). In vitro activity of conventional antifungal drugs and natural essences against the yeast-like alga Prototheca. J Antimicrob Chemother 61: 1312-1314 [Abstract] [Full Text]  
  • Lass-Florl, C., Mayr, A. (2007). Human Protothecosis. Clin. Microbiol. Rev. 20: 230-242 [Abstract] [Full Text]  
  • Marques, S., Silva, E., Carvalheira, J., Thompson, G. (2006). Short communication: In vitro antimicrobial susceptibility of Prototheca wickerhamii and Prototheca zopfii isolated from bovine mastitis.. J DAIRY SCI 89: 4202-4204 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»